ProTide man Chris McGuigan hopes to make Nucana the next Gilead
This article was originally published in Scrip
Executive Summary
There aren't many privately held UK-based pharmaceutical companies that can boast of appointing an inventor behind one of the world's biggest selling drugs to its management team. But Nucana's new CSO is Professor Chris McGuigan, the man behind ProTides, a technology used in drugs such as Gilead Sciences' Sovaldi (sofosbuvir). Here he tells Scrip what prompted him to cut down on his academic commitments for the first time in his career to take up a management position at a little-known oncology firm.